APA (7th ed.) Citation

EN, C., D, A., K, S., E, J., M, H., H, Z., . . . J, J. (2025). Biofluid biomarker changes following treatment with sabirnetug (ACU193) in INTERCEPT-AD, a phase 1 trial in early Alzheimer's disease. The journal of prevention of Alzheimer's disease, 12(4), 100082. https://doi.org/10.1016/j.tjpad.2025.100082

Chicago Style (17th ed.) Citation

EN, Cline, et al. "Biofluid Biomarker Changes Following Treatment with Sabirnetug (ACU193) in INTERCEPT-AD, a Phase 1 Trial in Early Alzheimer's Disease." The Journal of Prevention of Alzheimer's Disease 12, no. 4 (2025): 100082. https://doi.org/10.1016/j.tjpad.2025.100082.

MLA (9th ed.) Citation

EN, Cline, et al. "Biofluid Biomarker Changes Following Treatment with Sabirnetug (ACU193) in INTERCEPT-AD, a Phase 1 Trial in Early Alzheimer's Disease." The Journal of Prevention of Alzheimer's Disease, vol. 12, no. 4, 2025, p. 100082, https://doi.org/10.1016/j.tjpad.2025.100082.